Jump to content

Miran Rada

Add links
From Wikipedia, the free encyclopedia
Miran Rada
Born1983
Kurdistan region, Iraq
NationalityCanadian and Iraqi
Alma materUniversity of Leicester
Known forVessel co-option
Scientific career
FieldsBiochemistry and molecular biology

Miran Rada is a scientist of Kurdish-Iraqi descent, currently residing in Canada. He was born in the Kurdistan Region of Iraq and completed his undergraduate education at the University of Sulaimani. Rada earned his PhD in 2016 from University of Leicester,[1] focusing on oncology, which laid the foundation for his subsequent research endeavours. Rada emigrated to the United States, where he began his career at Albany Medical College in 2016. He moved to Canada to work at McGill University, eventually joining Komar University of Science and Technology.[2][3]

Rada's research has made significant contributions to understanding cancer biology,[4][5] particularly in the context of colorectal cancer and ovarian cancer.[6] He has extensively studied vessel co-option,[7] a process that tumors use to evade treatment and resist anti-cancer therapies. His work has highlighted the role of vessel co-option in anti-cancer resistance among patients with colorectal cancer liver metastases (CRCLMs)[8] and has also explored mechanisms behind cisplatin resistance in ovarian cancer.[9] Through both in vitro and in vivo studies, Rada has elucidated the molecular mechanisms underlying vessel co-option, providing valuable insights that could inform future therapeutic strategies against cancer.[10][11][12][13] His contributions are recognized within the scientific community, as he continues to advance research in oncology and related fields.[14][15]

References

[edit]
  1. ^ Rada, Miran. Thesis: Characterisation of Novel Post-translational Modulators of p53 (Thesis). University of Leicester.
  2. ^ Rada, Miran. "Miran Rada". Researchgate.
  3. ^ Rada, Miran. "Miran Rada". Komar University for Science and Technology.
  4. ^ Rada, Miran; Barlev, Nickolai; Macip, Salvador (2018-10-18). "BTK: a two-faced effector in cancer and tumour suppression". Cell Death & Disease. 9 (11): 1–3. doi:10.1038/s41419-018-1122-8. ISSN 2041-4889. PMC 6193937.
  5. ^ Rada, Miran; Lazaris, Anthoula; Kapelanski-Lamoureux, Audrey; Mayer, Thomas Z.; Metrakos, Peter (2021-06-01). "Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model". Seminars in Cancer Biology. Metastasis to the Liver: From Pathobiology through Therapies. 71: 52–64. doi:10.1016/j.semcancer.2020.09.001. ISSN 1044-579X.
  6. ^ "Dr. Miran Rada".
  7. ^ "Dana Massaro Is Building Her Family's Legacy". MUHC Foundation. Retrieved 2024-11-02.
  8. ^ Rada, Miran (2021). "Runt related transcription factor-1 plays a central role in vessel co-option of colorectal cancer liver metastases". Communications Biology. 4 (1): 950. doi:10.1038/s42003-021-02481-8. PMC 8355374. PMID 34376784.
  9. ^ Rada, Miran (2018). "Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer". Oncogene. 37 (35): 4809–4820. doi:10.1038/s41388-018-0297-x. PMID 29769618.
  10. ^ Rada, Miran. "No such thing as a healthy tan".
  11. ^ Rada, Miran. "MUHC hoping to extend lives with precision oncology". Global News.
  12. ^ Rada, Miran. "Miran Rada". Google Scholar.
  13. ^ Rada, Miran. "Miran Rada". UKH Journal of Science and Engneering.
  14. ^ Rada, Miran. "Dana Massaro is building her family's legacy". The Montrealer.
  15. ^ Rada, Miran. "Tumorigenesis Mechanism of Colorectal Cancer". MDPI_Cancers.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Miran_Rada&oldid=1257773849"